| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS20045750 | HPV | ENSG00000162434.14 | protein_coding | JAK1 | Yes | Yes | 3716 | P23458 Q6P669 |
| TVIS44024604 | HTLV-1 | ENSG00000162434.14 | protein_coding | JAK1 | Yes | Yes | 3716 | P23458 Q6P669 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | JAK1 |
|---|---|
| DrugBank ID | DB15091 |
| Drug Name | Upadacitinib |
| Target ID | BE0004145 |
| UniProt ID | P23458 |
| Regulation Type | inhibitor |
| PubMed IDs | 31692920; 30886973 |
| Citations | Biggioggero M, Becciolini A, Crotti C, Agape E, Favalli EG: Upadacitinib and filgotinib: the role of JAK1 selective inhibition in the treatment of rheumatoid arthritis. Drugs Context. 2019 Oct 24;8:212595. doi: 10.7573/dic.212595. eCollection 2019.@@Parmentier JM, Voss J, Graff C, Schwartz A, Argiriadi M, Friedman M, Camp HS, Padley RJ, George JS, Hyland D, Rosebraugh M, Wishart N, Olson L, Long AJ: In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494). BMC Rheumatol. 2018 Aug 28;2:23. doi: 10.1186/s41927-018-0031-x. eCollection 2018. |
| Groups | Approved; Investigational |
| Direct Classification | |
| SMILES | CC[C@@H]1CN(C[C@@H]1C1=CN=C2C=NC3=C(C=CN3)N12)C(=O)NCC(F)(F)F |
| Pathways | |
| PharmGKB | |
| ChEMBL | CHEMBL3622821 |
